Vol 9, Supplement 1 (February 28, 2020): Translational Lung Cancer Research (Mesothelioma: What We know and What We Do Not Know in 2020)

Editorial

This special volume of mesothelioma is dedicated to my friend Adi Gazdar
Michele Carbone
Translational Lung Cancer Research  
2020;
9
(Suppl 1)
:S1-S2
.
 (28 February 2020) 
PDF Full Text (1479) Open Access Get Permission

Review Article

Application of immunohistochemistry in diagnosis and management of malignant mesothelioma
David B. Chapel, Jefree J. Schulte, Aliya N. Husain, Thomas Krausz
Translational Lung Cancer Research  
2020;
9
(Suppl 1)
:S3-S27
.
 (28 February 2020) 
PDF Full Text (16279) Open Access Get Permission
Epidemiology of mesothelioma in the 21st century in Europe and the United States, 40 years after restricted/banned asbestos use
Naomi Alpert, Maaike van Gerwen, Emanuela Taioli
Translational Lung Cancer Research  
2020;
9
(Suppl 1)
:S28-S38
.
 (28 February 2020) 
PDF Full Text (8750) Open Access Get Permission
How asbestos and other fibers cause mesothelioma
Giovanni Gaudino, Jiaming Xue, Haining Yang
Translational Lung Cancer Research  
2020;
9
(Suppl 1)
:S39-S46
.
 (28 February 2020) 
PDF Full Text (9114) Open Access Get Permission
SV40 and human mesothelioma
Michele Carbone, Adi Gazdar, Janet S. Butel
Translational Lung Cancer Research  
2020;
9
(Suppl 1)
:S47-S59
.
 (28 February 2020) 
PDF Full Text (17668) Open Access Get Permission
BAP1: role in carcinogenesis and clinical implications
Daniel A. Kobrinski, Haining Yang, Muaiad Kittaneh
Translational Lung Cancer Research  
2020;
9
(Suppl 1)
:S60-S66
.
 (28 February 2020) 
PDF Full Text (5901) Open Access Get Permission
Mesothelioma developing in carriers of inherited genetic mutations
Yoshie Yoshikawa, Mitsuru Emi, Takashi Nakano, Giovanni Gaudino
Translational Lung Cancer Research  
2020;
9
(Suppl 1)
:S67-S76
.
 (28 February 2020) 
PDF Full Text (4396) Open Access Get Permission
Chemotherapy options versus “novel” therapies: how should we treat patients with malignant pleural mesothelioma
Maria J. Disselhorst, Paul Baas
Translational Lung Cancer Research  
2020;
9
(Suppl 1)
:S77-S85
.
 (28 February 2020) 
PDF Full Text (2192) Open Access Get Permission
Surgery for pleural mesothelioma, when it is indicated and why: arguments against surgery for malignant pleural mesothelioma
Gavitt A. Woodard, David M. Jablons
Translational Lung Cancer Research  
2020;
9
(Suppl 1)
:S86-S91
.
 (28 February 2020) 
PDF Full Text (4768) Open Access Get Permission
Chromosomal rearrangements and their neoantigenic potential in mesothelioma
Aaron Scott Mansfield, Tobias Peikert, George Vasmatzis
Translational Lung Cancer Research  
2020;
9
(Suppl 1)
:S92-S99
.
 (28 February 2020) 
PDF Full Text (2517) Open Access Get Permission
Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives
Steven G. Gray, Luciano Mutti
Translational Lung Cancer Research  
2020;
9
(Suppl 1)
:S100-S119
.
 (28 February 2020) 
PDF Full Text (11756) Open Access Get Permission
Peritoneal mesothelioma
Alissa Greenbaum, H. Richard Alexander
Translational Lung Cancer Research  
2020;
9
(Suppl 1)
:S120-S132
.
 (28 February 2020) 
PDF Full Text (5868) Open Access Get Permission

Obituary

Adi Gazdar, MD: one of the founders of the molecular pathology of cancer, a great scientist and a great man
John D. Minna
Translational Lung Cancer Research  
2020;
9
(Suppl 1)
:S133-S136
.
 (28 February 2020) 
PDF Full Text (1835) Open Access Get Permission

Disclosure:

The supplement “Mesothelioma: What We know and What We Do Not Know in 2020” was commissioned by the editorial office, Translational Lung Cancer Research without any sponsorship or funding. Michele Carbone served as the unpaid Guest Editor for the supplement.